News

February 17, 2017February 17, 2017

RA Patients Treated with Olumiant Show Improvements Compared to Humira, Placebo

In a pivotal Phase 3 clinical trial, Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to Humira (adalimumab) and placebo, according to a ... Read more

February 15, 2017February 15, 2017

European Commission OKs Marketing Olumiant Tablets for Adults with Active RA

News, rheumatoid arthritis

The European Commission has granted marketing authorization for Olumiant (baricitinib) 4 mg and 2 mg tablets for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have ... Read more

February 13, 2017February 13, 2017

Newly Identified Genes May Contribute to Arthritis Risk in Arabs, Study Shows

News

A large genetic study confirmed that Arabs share a rheumatoid arthritis risk gene with other populations, but identified new genes that may be involved in triggering the disease in Arabs ... Read more

February 10, 2017February 10, 2017

Logan Levkoff Partners with Pfizer to Talk About Sex and Relationships for RA, Chronic Disease Patients

News

Relationship expert and author Logan Levkoff, PhD, is partnering with Pfizer to address intimacy and relationship issues for people living with rheumatoid arthritis (RA) and other chronic diseases. Levkoff , ... Read more

February 8, 2017February 8, 2017

Sanofi’s Kevzara Approved in Canada as Treatment for Moderate to Severe RA

News

Kevzara (sarilumab) has been approved in Canada as a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) who are either intolerant or considered inappropriate candidates to be treated ... Read more

February 6, 2017February 6, 2017

Newly Identified T-cell in RA Patients May Leapfrog Autoimmune Treatment Development

News, rheumatoid arthritis

An entirely new type of T-cell found in people with rheumatoid arthritis works in a unique way to drive disease processes in the joints by teaming up with other immune ... Read more

February 3, 2017February 3, 2017

CHMP Favors Xeljanz Be Approved to Treat Patients with Active Rheumatoid Arthritis in EU

News

The Committee for Medicinal Products for Human Use (CHMP) is recommending the approval of Pfizer’s Xeljanz (tofacitinib citrate, 5 mg tablets twice daily) as a treatment for adults with moderate-to-severely active rheumatoid arthritis (RA) in ... Read more

February 1, 2017February 1, 2017

EU Closer to Approving ABP 501 as Alternative to Humira for Rheumatoid Arthritis

News, rheumatoid arthritis

Amgen has taken a key step toward obtaining European Union approval of its ABP 501 biosimilar therapy for rheumatoid arthritis (RA) and other conditions. The European Medicines Agency’s Committee for Medicinal Products for Human ... Read more

January 30, 2017January 30, 2017

NIH Awards $1.8M to Study of Enzyme’s Role in Potential Therapies for RA and Other Diseases

News, rheumatoid arthritis

A nearly $1.8 million grant given a research team at The Scripps Research Institute (TSRI) in Florida will be used to study an enzyme that controls cell survival and death, with the goal ... Read more

January 27, 2017January 27, 2017

Real-time Imaging Used to Identify Protein That Triggers Inflammatory Arthritis

News

Using a novel imaging technique, researchers followed in real time the movement of immune cells in a live mouse and identified a key factor responsible for triggering inflammatory arthritis. The ... Read more